Lincoln Park Capital Fund is a Chicago-based asset management firm focused on opportunistic investing in public and private companies.
Business Model:
Revenue: $0
Employees: 0-0
Address: 440 N Wells Street Suite 410
City: Chicago
State: IL
Zip: 60654
Country: US
Lincolnpark Capital is an asset management firm that focuses on investing in real estate sector.
Contact Phone:
+13128229300
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2021 | Gridiron BioNutrients | Series B | 4M |
3/2022 | Biodesix | Post-IPO Equity | 0 |
1/2018 | InVivo Therapeutics | Post-IPO Equity | 15.2M |
3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
5/2011 | Lightwave Logic | Post-IPO Equity | 20M |
1/2019 | Lightwave Logic | Post-IPO Equity | 25M |
2/2013 | Nuo Therapeutics | Private Equity Round | 27.5M |
8/2010 | Raptor Pharmaceuticals | Post-IPO Equity | 0 |
3/2020 | Emmaus Medical | Post-IPO Equity | 25M |
4/2022 | Aquestive Therapeutics | Post-IPO Equity | 40M |
7/2014 | Ocata Therapeutics | Post-IPO Equity | 30M |
9/2010 | Onstream Media | Post-IPO Equity | 900k |
4/2020 | Dare Bioscience | Post-IPO Equity | 15M |
2/2019 | rMark Bio | Seed Round | 1.5M |
10/2010 | Nuo Therapeutics | Post-IPO Equity | 13M |
4/2014 | Phio Pharmaceuticals | Post-IPO Equity | 20M |
1/2021 | Aileron Therapeutics | Post-IPO Secondary | 35.9M |
6/2022 | Evaxion Biotech | Post-IPO Equity | 40M |
1/2021 | Onconova Therapeutics | Post-IPO Equity | 0 |
6/2021 | Ocuphire Pharma | Post-IPO Equity | 15M |
11/2022 | PaxMedica | Post-IPO Equity | 20M |
6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
2/2014 | Plandai Biotechnology | Post-IPO Equity | 15.3M |
7/2019 | Leap Therapeutics | Post-IPO Equity | 21M |
12/2022 | Marker Therapeutics | Post-IPO Equity | 25M |
4/2014 | Elite Pharmaceuticals | Post-IPO Equity | 800k |
8/2022 | Kintara Therapeutics | Post-IPO Equity | 0 |
8/2022 | Kintara Therapeutics | Post-IPO Equity | 0 |
6/2022 | Evaxion Biotech | Post-IPO Equity | 0 |
4/2022 | Aquestive Therapeutics | Post-IPO Equity | 0 |
3/2022 | Biodesix | Post-IPO Equity | 0 |
11/2021 | Gridiron BioNutrients | Post-IPO Equity | 0 |
6/2021 | Ocuphire Pharma | Post-IPO Equity | 0 |
6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
1/2021 | Onconova Therapeutics | Post-IPO Equity | 0 |
1/2021 | Aileron Therapeutics | Post-IPO Secondary | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|